The change of retinal sensitivity with intravitreal injection of aflibercept for wet type of age-related macular degeneration.

The change of retinal sensitivity with intravitreal injection of aflibercept for wet type of age-related macular degeneration. - The change of retinal sensitivity with IVA for AMD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015810

Enrollment

Registered

2015-01-01

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

wet type age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients who received informed consent and agreed the investigation 2)man or woman 50 years or older 3)patiens with typical AMD or polypoidal chorodal vasculopathy 4)treatment naive for AMD 5)decimal visual acuity within 0.1 to 1.2

Exclusion criteria

Exclusion criteria: 1.Patients who need to undergo intravitreal injection of aflibercept for their both eyes. 2.The lesion is more than 12 disc diameter area with fluorecein angiography 3.Subretinal hemorrhage with 50 percent or more of the lesion area 4.Subretinal scar or fibrosis with 50 percent or more of the lesion area 5.retinal pigment epithelium tear 6.patients who had past stage 3 or 4 macular hole 7.patients who received the therapy with triamcinolone acetonide within 6 months 8.patients who received the therapy with Dexamethasone within 30 days 9.patients who received intra occular surgery within 6 months 10.patients who received pars plana vitrectomy or submacular surgery 11.patinets with intra or external occular infection or inflamation 12.patients with uveitis in any eye 13.fluorescein or indocianine green alergy 14.pregnancy or possibility of pregnancy or woman who are lactating 15.patient who are judged unsuitable for the investigation by the doctor

Design outcomes

Primary

Measure	Time frame
The change amount of retinal sensitivity at six month from base line after initial therapy of intravitreal injection of aflibercept for wet type of age-related macular degeneration	—

Secondary

Measure	Time frame
1.The ratio of patients with improvement or preservation of visual acuity after intravitreal injection of aflibercept 2.The change amount of visual aquity at 1,3,6,12 months from base line 3.The change amount of central foveal thickness at 1,3,6,12 months from base line 4.The ratio of patients with subretinal or intraretinal exdative change at 6 and 12 months 5.The change amount of retinal sensitivity at 1,3 and 12 months from base line	—

Measure

Time frame

1.The ratio of patients with improvement or preservation of visual acuity after intravitreal injection of aflibercept 2.The change amount of visual aquity at 1,3,6,12 months from base line 3.The change amount of central foveal thickness at 1,3,6,12 months from base line 4.The ratio of patients with subretinal or intraretinal exdative change at 6 and 12 months 5.The change amount of retinal sensitivity at 1,3 and 12 months from base line

—

Countries

Japan

Contacts

Public ContactMasayasu Kitahashi

Chiba University Graduate School of Medicine Department of Ophthalmology and Visual Science

kitahashi@faculty.chiba-u.jp043-222-7171

Outcome results